Please login to the form below

Not currently logged in

Agility Award in Pharma Market Excellence

Sponsored by

Back to Results


Launching Takhzyro: Re-defining the Rules for Treatment Initiation

by Takeda UK
with support from Makara Health

Summary of work

Hereditary Angioedema (HAE) is a rare, potentially fatal, genetic disorder, characterised by painful swelling attacks that can occur without warning and last for days.

In January 2020, Takeda launched Takhzyro▼ for the prevention of HAE attacks in patients aged 12 and older. The initiation of new patients onto Takhzyro typically involves the first 1-2 doses being administered in a hospital by a healthcare professional (HCP), before being transferred to a home setting.

Takhzyro was just six weeks into launch when COVID-19 took effect, preventing hospital appointments and putting patient treatments at risk. Anxiety increases the risk of HAE attacks; getting treatment to vulnerable HAE patients was critical during the stressful pandemic. Working with UCLH NHS Foundation Trust and Barts Health NHS Trust, Takeda redesigned existing processes to facilitate Takhzyro ‘at-home initiation’: HCPs consulted patients remotely, followed by one-to-one patient training with a homecare company ensuring patients were safe and confident to administer Takhzyro at home.

It took two weeks from lockdown to develop the Takhzyro ‘at-home initiation’ concept, and only another two weeks to implement. Patients who would not have benefited from treatment have, due to Takeda’s agile response to the worsening pandemic.

Judges' comments

There was a clear link to patient impact in this initiative and the launch clearly delivered a new service in challenging times. Launching Takhzyro had a real focus on patients, with one-to-one coaching and patient-centric implementation that really demonstrated success.


Accord’s Agility Ensures Medicines Supply During COVID-19 - by Accord Healthcare Ltd
with support from Alexa Forbes Consulting Ltd


“Switch 4 Them” - Protecting Vulnerable Patients During a Pandemic - by Bayer

Supporting Alcohol Teams through the Global COVID19 Pandemic - by Kyowa Kirin
with support from Ann Taylor, Adam Winstock, Liz Gilligan, Adrian Brown, Anthony Gartland

Launching Takhzyro: Re-defining the Rules for Treatment Initiation - by Takeda UK
with support from Makara Health

Entyvio® (vedolizumab) Subcutaneous Launch: Not Making a Drama Out of a Crisis - by Takeda UK Ltd
with support from Aurora Healthcare Communications

Key dates

Entry deadline 26 August 2022
Extended entry deadline 2 September 2022*
*additional fee applies
Judging Day 6 October 2022
Company/Team of the Year Interviews 21 October 2022
PMEA Event 23 November 2022